

**Supplemental Table 1. Sensitivities and Specificities for CAC and Functional Testing**

	Sensitivity (95% CI)			Specificity (95% CI)		
	CAC Testing	Functional testing	p-value	CAC Testing	Functional testing	p-value
<b>All-cause death/MI/UA</b>						
Abnormal: (CAC>0; FT=mild/moderate/severe)	84.2% (76.9–90.0)	43.2% (34.6–52.1)	<0.001	35.2% (33.8–36.7)	78.6% (77.4–79.8)	<0.001
Abnormal: (CAC>100; FT=moderate/severe)	60.9% (52.1–69.2)	36.4% (28.2–45.2)	<0.001	67.3% (65.9–68.8)	88.1% (87.1–89.0)	<0.001
Abnormal: (CAC>400; FT=severe)	30.8% (23.1–39.4)	26.5% (19.2–34.9)	0.498	85.3% (84.2–86.4)	92.6% (91.8–93.4)	<0.001
<b>Cardiovascular death/MI/UA</b>						
Abnormal: (CAC>0; FT=mild/moderate/severe)	86.8% (78.8–92.6)	48.1% (38.4–58.0)	<0.001	35.2% (33.7–36.7)	78.6% (77.4–79.8)	<0.001
Abnormal: (CAC>100; FT=moderate/severe)	63.2% (53.3–72.4)	40.7% (31.4–50.6)	0.001	67.2% (65.8–68.7)	88.0% (87.0–89.0)	<0.001
Abnormal: (CAC>400; FT=severe)	33.0% (24.2–42.8)	28.7% (20.4–38.2)	0.555	85.3% (84.1–86.3)	92.6% (91.8–93.3)	<0.001
<b>Cardiovascular death/MI</b>						
Abnormal: (CAC>0; FT=mild/moderate/severe)	83.0% (70.2–91.9)	33.3% (22.7–45.4)	<0.001	34.8% (33.4–36.3)	78.1% (76.9–79.3)	<0.001
Abnormal: (CAC>100; FT=moderate/severe)	50.9% (36.8–64.9)	26.4% (16.7–38.1)	0.008	66.7% (65.2–68.1)	87.6% (86.6–88.5)	<0.001
Abnormal: (CAC>400; FT=severe)	24.5% (13.8–38.3)	19.4% (11.1–30.5)	0.517	84.9% (83.8–88.3)	92.3% (91.4–93.0)	<0.001

MI indicates myocardial infarction; UA, unstable angina.

**Supplemental Table 2: Alternative Cutpoints for CAC—Frequency of Test Findings and Association With Clinical Events for CAC Testing**

<b>Initial Test Results</b>	<b>CAC Testing (N=4209)</b>				<b>Functional Testing (N=4602)</b>			
	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>
<b>All-cause death/MI/UA</b>								
Normal (CAC 0, FT = normal)	1457/4209 (34.6)	21/1457 (1.44)			3588/4602 (78.0)	75/3588 (2.1)		
Mild (CAC 1-99, FT = mild)	1340/4209 (31.8)	31/1340 (2.31)	1.51 (0.86–2.64)	0.149	432/4602 (9.4)	9/432 (2.1)	0.94 (0.47–1.89)	0.867
Moderate (CAC 100-300, FT moderate)	621/4209 (14.8)	32/621 (5.15)	3.18 (1.80–5.62)	<0.001	217/4602 (4.7)	13/217 (6.0)	2.65 (1.46–4.83)	0.001
Severe (CAC >300, FT Severe)	791/4209 (18.8)	49/791 (6.19)	3.42 (1.95–5.99)	<0.001	365/4602 (7.9)	35/365 (9.6)	3.88 (2.58–5.85)	<0.001
<b>Cardiovascular death/MI/UA</b>								
Normal (CAC 0, FT = normal)	1457/4209 (34.6)	14/1457 (0.96)			3588/4602 (78.0)	56/3588 (1.6)		
Mild (CAC 1-99, FT = mild)	1340/4209 (31.8)	25/1340 (1.87)	1.84 (0.95–3.56)	0.070	432/4602 (9.4)	8/432 (1.9)	1.11 (0.53–2.34)	0.783
Moderate (CAC 100-300, FT moderate)	621/4209 (14.8)	27/621 (4.35)	4.08 (2.10–7.93)	<0.001	217/4602 (4.7)	13/217 (6.0)	3.50 (1.89–6.48)	<0.001
Severe (CAC >300, FT Severe)	791/4209 (18.8)	40/791 (5.06)	4.29 (2.22–8.30)	<0.001	365/4602 (7.9)	31/365 (8.5)	4.59 (2.93–7.19)	<0.001
<b>Cardiovascular death/MI</b>								
Normal (CAC <0, FT = normal)	1457/4209 (34.6)	9/1457 (0.62)			3588/4602 (78.0)	48/3588 (1.3)		
Mild (CAC 1-99, FT = mild)	1340/4209 (31.8)	17/1340 (1.27)	1.77 (0.78–4.02)	0.171	432/4602 (9.4)	5/432 (1.2)	0.81 (0.32–2.04)	0.654
Moderate (CAC 100-300, FT moderate)	621/4209 (14.8)	11/621 (1.77)	2.17 (0.87–5.41)	0.095	217/4602 (4.7)	5/217 (2.3)	1.53 (0.60–3.90)	0.368

**SUPPLEMENTAL TABLES**  
 DOI: 10.1161/CIRCULATIONAHA.117.030578

<b>Initial Test Results</b>	<b>CAC Testing (N=4209)</b>				<b>Functional Testing (N=4602)</b>			
	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>
Severe (CAC >300, FT Severe)	791/4209 (18.8)	16/791 (2.02)	2.00 (0.82–4.89)	0.130	365/4602 (7.9)	14/365 (3.8)	2.13 (1.16–3.91)	0.014

\* Hazard ratios (HR) adjusted for age, sex, CAD risk equivalent (history of either diabetes mellitus, peripheral artery disease, or cerebrovascular disease), and the prespecification of the intended functional test (if randomly assigned to the functional testing arm).

**Supplemental Table 3: Alternative Cutpoints for CAC—Frequency of Test Findings and Association With Clinical Events for CAC Testing**

<b>Initial Test Results</b>	<b>CAC Testing (N=4209)</b>				<b>Functional Testing (N=4602)</b>			
	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>
<b>All-cause death/MI/UA</b>								
Normal (CAC <10, FT = normal)	1831/4209 (43.5)	28/1831 (1.53)			3588/4602 (78.0)	75/3588 (2.1)		
Mild (CAC 10-99, FT = mild)	966/4209 (23.0)	24/966 (2.48)	1.52 (0.87–2.63)	0.139	432/4602 (9.4)	9/432 (2.1)	0.94 (0.47–1.89)	0.867
Moderate (CAC 100-400, FT moderate)	621/4209 (14.8)	32/621 (5.15)	3.02 (1.79–5.10)	<0.001	217/4602 (4.7)	13/217 (6.0)	2.65 (1.46–4.83)	0.001
Severe (CAC >400, FT Severe)	791/4209 (18.8)	49/791 (6.19)	3.24 (1.94–5.42)	<0.001	365/4602 (7.9)	35/365 (9.6)	3.88 (2.58–5.85)	<0.001
<b>Cardiovascular death/MI/UA</b>								
Normal (CAC <10, FT = normal)	1831/4209 (43.5)	18/1831 (0.98)			3588/4602 (78.0)	56/3588 (1.6)		
Mild (CAC 10-99, FT = mild)	966/4209 (23.0)	21/966 (2.17)	2.08 (1.10–3.94)	0.024	432/4602 (9.4)	8/432 (1.9)	1.11 (0.53–2.34)	0.783
Moderate (CAC 100-400, FT moderate)	621/4209 (14.8)	27/621 (4.35)	4.02 (2.17–7.44)	<0.001	217/4602 (4.7)	13/217 (6.0)	3.50 (1.89–6.48)	<0.001
Severe (CAC >400, FT Severe)	791/4209 (18.8)	40/791 (5.06)	4.25 (2.31–7.81)	<0.001	365/4602 (7.9)	31/365 (8.5)	4.59 (2.93–7.19)	<0.001
<b>Cardiovascular death/MI</b>								
Normal (CAC <10, FT = normal)	1831/4209 (43.5)	12/1831 (0.66)			3588/4602 (78.0)	48/3588 (1.3)		
Mild (CAC 10-99, FT = mild)	966/4209 (23.0)	14/966 (1.45)	1.88 (0.86–4.11)	0.155	432/4602 (9.4)	5/432 (1.2)	0.81 (0.32–2.04)	0.654
Moderate (CAC 100-400, FT moderate)	621/4209 (14.8)	11/621 (1.77)	2.08 (0.89–4.86)	0.089	217/4602 (4.7)	5/217 (2.3)	1.53 (0.60–3.90)	0.368

**SUPPLEMENTAL TABLES**  
 DOI: 10.1161/CIRCULATIONAHA.117.030578

<b>Initial Test Results</b>	<b>CAC Testing (N=4209)</b>				<b>Functional Testing (N=4602)</b>			
	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>
Severe (CAC >400, FT Severe)	791/4209 (18.8)	16/791 (2.02)	1.92 (0.84–4.39)	0.122	365/4602 (7.9)	14/365 (3.8)	2.13 (1.16–3.91)	0.014

\* Hazard ratios (HR) adjusted for age, sex, CAD risk equivalent (history of either diabetes mellitus, peripheral artery disease, or cerebrovascular disease), and the prespecification of the intended functional test (if randomly assigned to the functional testing arm).

**Supplemental Table 4. Frequency of Abnormal and Normal Test Findings and Association With Clinical Events for Anatomic and**

<b>Initial Test Results</b>	<b>CAC Testing (N=4209)</b>				<b>Functional Testing (N=4602)</b>			
	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>	<b>Frequency n/N (%)</b>	<b>Event Rate n/N (%)</b>	<b>HR* (95% CI)</b>	<b>P-value</b>
<b>All-cause death/MI/UA</b>								
Normal (CAC=0; FT=normal)	1457/4209 (34.62)	21/1457 (1.44)			3588/4602 (77.97)	75/3588 (2.09)		
Abnormal (CAC>0; FT=mild/moderate/severe)	2752/4209 (65.38)	112/2752 (4.07)	2.30 (1.41– 3.74)	0.001	1014/4602 (22.03)	57/1014 (5.62)	2.42 (1.70– 3.44)	<0.001
<b>Cardiovascular death/MI/UA</b>								
Normal (CAC=0; FT=normal)	1457/4209 (34.62)	14/1457 (0.96)			3588/4602 (77.97)	56/3588 (1.56)		
Abnormal (CAC>0; FT=mild/moderate/severe)	2752/4209 (65.38)	92/2752 (3.34)	2.86 (1.60– 5.13)	<0.001	1014/4602 (22.03)	52/1014 (5.13)	2.93 (2.00– 4.30)	<0.001
<b>Cardiovascular death/MI</b>								
Normal (CAC=0; FT=normal)	1457/4209 (34.62)	9/1457 (0.62)			3588/4602 (77.97)	48/3588 (1.34)		
Abnormal (CAC>0; FT=mild/moderate/severe)	2752/4209 (65.38)	44/2752 (1.60)	1.92 (0.90– 4.07)	0.090	1014/4602 (22.03)	24/1014 (2.37)	1.50 (0.91– 2.46)	0.112

**Functional Testing.**

MI indicates myocardial infarction; UA, unstable angina.

\* Hazard ratios (HR) adjusted for age, sex, CAD risk equivalent (history of either diabetes mellitus, peripheral artery disease, or cerebrovascular disease), and the prespecification of the intended functional test (if randomly assigned to the functional testing arm).